Mode
Text Size
Log in / Sign up
Phase 4 N=324 Randomized Single-blind Treatment

An Efficacy Study of Chlorhexidine Mouthwashes

Gingivitis

Enrolled (actual)
324
Serious AEs
0.3%
Results posted
Jul 2014
Primary outcome: Primary: Gingival Severity Index (GSI) Based on the Gingival Index (GI) — 0.152; 0.143; 0.212 Units on a scale — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Chlorhexidine Digluconate Mouthwash with Alcohol (Drug); Chlorhexidine Digluconate Mouthwash without Alcohol (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Mar 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Gingival Severity Index (GSI) Based on the Gingival Index (GI)
0.152; 0.143; 0.212 <0.0001 sig
SECONDARY
Gingival Index
1.12; 1.11; 1.19 <0.0001 sig
SECONDARY
Turesky Modification of Quigley & Hein Plaque Index for Overall Plaque Scores
2.50; 2.40; 3.34 <0.0001 sig
SECONDARY
Turesky Modification of Quigley & Hein Plaque Index for Interproximal Plaque Scores
2.77; 2.63; 3.69 <0.0001 sig

Summary

The aim of this study is to compare subject gingival health after 6 weeks of twice daily use of a non-alcohol or alcohol containing mouthrinse and brushing compared to brushing only.

Eligibility Criteria

Inclusion Criteria

  • Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral/ dental examination.
  • a) Good oral health in the opinion of the investigator (allowing mild to moderate gingivitis to meet entry criteria).

b) A minimum of 20 permanent gradable teeth at screening. (Gradable teeth are those where restorative materials cover less than 25% of the tooth surface graded).

c) Mild to moderate gingivitis present at the screening visit in the opinion of the investigator.

d) Positive response to bleeding on brushing exercise at screening visit. e) A total of 20 bleeding sites or greater at baseline visit.

Exclusion Criteria

  • Known or suspected intolerance or hypersensitivity to Chlorhexidine or other study materials (or closely related compounds) or any of their stated ingredients.
  • 5. a) Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any other medical condition (e.g. Diabetes Mellitus) that would make the subject unlikely to fully complete the study or any that increases the risk to the subject or undermines the data validity.

b) Subjects requiring prophylactic antibiotic treatment prior to dental therapy.

c) Use of concomitant medication that, in the opinion of the investigator, might interfere with the outcome of the study or increases the risk to the subject (eg: phenytoin, calcium antagonists, cyclosporine, warfarin, antibiotics, immuno-suppressants).

d) Use of antibiotics within two weeks prior to the screening visit or throughout the study.

e) Use of any systemic medication which would have an effect on gingival conditions within 14 days of gingival examinations (eg: ibuprofen or aspirin therapy) 6. a) Have current active caries b) More than 3 pockets with 5mm or over. c) Excessive calculus present that interferes with the probing examination for Gingival Index.

d) Other severe oral/ gingival conditions (e.g. Acute Necrotizing Ulcerative Gingivitis) that may compromise the study or the subjects in the opinion of the investigator or gingivitis examiner.

e) Medical conditions which may directly influence gingival bleeding. f) Restorations in a poor state of repair. g) Orthodontic appliances anterior cosmetic restorations and veneers. h) Enamel pitting/irregularities. 7. Subjects using chewing tobacco, pan, pan-masala, gutkha or other chewing tobacco products or subjects who have quit using any of those within the past six months prior to screening.

  • b) An employee of any toothpaste manufacturer or their immediate family.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01751178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search